Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02423291

Study Title
A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL (FIL_SGN01) (NCT02423291)

Trial Description
Study Objectives Primary:

  • To determine the antitumor efficacy of single-agent brentuximab vedotin/SGN-035 (1.8 mg/kg administered intravenously every 3 weeks) as measured by the overall objective response rate in patients with relapsed or refractory primary mediastinal large B-cell lymphoma.

Secondary:

  • To assess duration of tumor control, including duration of response and progression-free survival
  • To assess survival
  • To assess the safety and tolerability of brentuximab vedotin

Additional:

  • To assess disease-related symptoms

Number of Planned Patients 20 patients will be enrolled in this study. Duration of the study The study duration is 18 months for enrollment and 2 years for the follow-up.

This study is sponsored by Fondazione Italiana Linfomi ONLUS [1]

Study Data

  • Condition: Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 20
  • Start: October 2013
  • Estimated Completion: December 2018
  • Last verified: April 2015

Study Schematic

(Coming soon)


Last Editorial review: July 6, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar